Nasdaq Breakout Idea (CVKD) Jumps Early On Breaking News (Low Float Under 5Mn Shares)
CVKD comes out stomping early and could start testing the $1.00 level early.
Part of today's green push could be attributed to the company's huge breaking news this morning.
Check it out:
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress
Tecarfarin is the only known Novel Vitamin K Antagonist in Development
PONTE VEDRA, Fla., Sept. 5, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today cited recent data that underscores additional need for an improved Vitamin K Antagonist (VKA). The Company believes tecarfarin is the solution for this unmet need.
At the recent European Society of Cardiology Congress (ESC) in Amsterdam, The Netherlands, the open-label "FRAIL-AF" trial was presented, revealing that switching International Normalized Ratio (INR)-guided VKA treatment to direct oral anticoagulants (DOACs aka NOACs) in frail older patients with Atrial Fibrillation (AFib) was associated with more bleeding complications compared to continuing VKA treatment, without an associated reduction in thromboembolic complications. Reports indicate that this unique trial was stopped early for futility in seeking superiority for the direct oral anticoagulant (DOAC) strategy. FRAIL-AF was deemed the most important study from ESC, according to Medscape.
In the report, study author Geert-Jan Geersing, MD, PhD, of the University Medical Center Utrecht in the Netherlands, at the ESC Congress concluded that "Switching from a VKA to a NOAC should not be considered without a clear indication in frail older patients with AFib."
Cadrenal is developing tecarfarin, a novel Vitamin K Antagonist, targeted for indications where existing VKAs fail to achieve sufficiently stable anticoagulation and DOACs (Eliquis-class drugs) are not widely prescribed.
"The findings of the FRAIL-AF study highlight the benefits of VKAs compared to DOACs in an additional unique patient population," commented Quang Pham, CEO of Cadrenal Therapeutics. "Tecarfarin, an enhanced VKA, avoids the existing metabolism problems of currently available VKAs by using an alternate metabolic pathway. We believe tecarfarin will provide improved outcomes for patients with certain rare medical conditions. Cadrenal has identified three such rare medical conditions: End-Stage Kidney Disease (ESKD) with Atrial Fibrillation (AFib); Left Ventricular Assist Devices (LVADs); and Antiphospholipid Syndrome (APS)."
Currently, tecarfarin has orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with ESKD and AFib, providing for 7-year marketing exclusivity.
Based on management's market analysis studies and expected adoption rates, these three rare medical conditions present a U.S. market opportunity in excess of $2Bn per year.
Read the full article here.
Remember, this is a low float profile which means volatility can take hold in a second.
With Yahoo Finance reporting a float of fewer than 5Mn shares and today's big news, CVKD needs to be on radar now.
Read my initial report below and get CVKD pulled up quickly.
It's crystal clear why anyone should aggressively follow a biopharmaceutical company on the brink of releasing a groundbreaking anticoagulant.
Lives are at stake, and we're talking about preventing heart attacks, strokes, and deaths here!
For patients with rare medical conditions that make them prone to blood clots, this could be their lifeline.
The existing treatments are archaic, demanding constant monitoring, dietary restrictions, and they still come with significant risks.
Right now, one company's progress towards a better-functioning anticoagulant treatment could lead to a revolutionary shift in healthcare.
Imagine a world where these patients no longer have to endure the hardships of older anticoagulants, where they can have a safer, more convenient option right at their fingertips.
This is more than just a medical development; it's a beacon of hope for countless individuals living with the constant fear of life-threatening clots.
And let's not forget, pushing for such innovations can lead to reduced healthcare costs, improved patient well-being, and even economic growth.
That's why with a flagship therapy that's Phase 3-ready, a low float of fewer than 4Mn shares, huge August news regarding new addressable markets, a 2023 addition to the Nasdaq CM, and a 2023 Fast Track designation, this biopharma company could start gaining traction way ahead of 2024.
Drop everything and pull up this Nasdaq breakout idea:
*Cadrenal Therapeutics, Inc. (CVKD)*
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner), to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain rare medical conditions.
Tecarfarin has orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, and atrial fibrillation.
And based on several potential breakout catalysts, CVKD needs to be on your radar this second. Check 'em out:
No. 1 - Volatility Could Be Significant Based On CVKD's Low Float Size
No. 2 - Huge August News Brings In New Addressable Market Potential
No. 3 - 2023's Bombshell News (U.S. FDA Grants Fast Track Designation To Tecarfarin)
No. 4 - Exposure Could Be Growing As CVKD Joins The Nasdaq CM In 2023
No. 5 - Company Strengthens Board With Industry Leader (Former CCO Of Arena Pharmaceuticals)
But more on those in a second...
CVKD's Focus: End-Stage Renal Disease and Atrial Fibrillation (ESRD + AFib)
Patients with end-stage renal disease and AFib represent a spectrum of disorders involving both the heart and kidneys (known as cardiorenal syndrome or CRS) in which acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ.
There are currently no effective treatment options for patients with end-stage renal disease and AFib.
Commonly prescribed treatments, such as warfarin and apixaban, may cause substantial harm, leading to outcomes such as stroke, systemic embolism, major bleeding, or death. Yet most trials of anticoagulant therapy to reduce the risk of such events have excluded these patients.
These patients have typically been excluded from randomized clinical trials because approved therapies for AFib have metabolic profiles that may increase drug exposures in patients thereby increasing known risks and challenges in managing patients with ESRD + AFib.
AFib is the most common arrhythmia, with its incidence and prevalence increasing over the last 20 years.
There are more than 809,000 Americans with ESRD, with approximately 70% on dialysis. Approximately 150,000 ESRD patients also have AFib.
AFib nearly doubles the anticipated mortality and increases the stroke risk by approximately five-fold in these patients.
Their lead drug candidate, tecarfarin, targets a different metabolic pathway than the most commonly prescribed drugs for the treatment of thrombosis and AFib in order to potentially eliminate specific side effects while maintaining or improving effectiveness.
Tecarfarin has been evaluated in 11 human clinical trials in over a thousand individuals.
In Phase 1, Phase 2 and Phase 2/3 clinical trials that have been conducted thus far, tecarfarin has generally been well-tolerated in both healthy adult patients and patients with ESRD and chronic kidney disease.
Tecarfarin Looks to Solve Warfarin’s Major Problems
Tecarfarin potentially provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding